Research programme: thorium-227 radiolabelled antibodies - Bayer/Progenics

Drug Profile

Research programme: thorium-227 radiolabelled antibodies - Bayer/Progenics

Alternative Names: 1095 - Bayer/Progenics; MIP 1095 I-131; PSMA targeted therapeutics; PSMA-ADC

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator Bayer
  • Class Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 05 May 2016 Preclinical trials in Prostate cancer in Germany (Parenteral)
  • 05 May 2016 Progenics plans a phase I trial for Prostate cancer (Metastatic disease) in USA
  • 02 May 2016 Early research in Prostate cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top